Pfizer reported quarterly results that beat estimates and raised the low end of its revenue guidance, driven by strong sales of non‑COVID products. However, it reduced its full‑year revenue outlook for COVID‑related products to $4 billion from about $5 billion.
Impact: The beat and higher guidance are likely to support Pfizer's share price in the short term.
Not investment advice